VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Research

• Publication date

  2011-05-25

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-10-2527PMID 21613405PMCID PMC3138890
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting the HGF/Met signalling pathway in cancer.

  2010cited by this paper
• R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.

  2010cited by this paper
• An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies

  2010cited by this paper
• Cutting off cancer's supply lines

  2009cited by this paper
• Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

  2009influential reference
• E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.

  2009cited by this paper
• Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis

  2009cited by this paper
• Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

  2009cited by this paper
• Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

  2009influential reference
• Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.

  2009cited by this paper
• Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

  2009cited by this paper
• Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

  2009cited by this paper
• A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC)

  2008influential reference
• Beyond VEGF: targeting tumor growth and angiogenesis via alternative mechanisms.

  2008cited by this paper
• HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.

  2008cited by this paper
• Modes of resistance to anti-angiogenic therapy

  2008cited by this paper
• The MET receptor tyrosine kinase in invasion and metastasis

  2007cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2007cited by this paper
• Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

  2007cited by this paper
• A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies

  2007influential reference
• Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM)

  2007cited by this paper
• Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

  2007cited by this paper
• FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.

  2007cited by this paper
• A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo

  2006cited by this paper
• 104 POSTER Simultaneous blockade of VEGF and HGF receptors results in potent anti-angiogenic and anti-tumor effects

  2006cited by this paper
• Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?

  2006cited by this paper
• Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

  2006influential reference
• VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.

  2006cited by this paper
• Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.

  2006cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2006cited by this paper
• Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors.

  2006cited by this paper
• Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

  2005cited by this paper
• Angiogenesis as a therapeutic target

  2005cited by this paper
• 141 The spectrum-selective kinase inhibitor EXEL-0999 inhibits mitogenic and angiogenic kinases, and causes rapid tumor vasculature destruction and regression in mouse xenograft models

  2004cited by this paper
• Targeting the tumor and its microenvironment by a dual-function decoy Met receptor.

  2004cited by this paper
• Age-Related Changes in Vascular Endothelial Growth Factor Dependency and Angiopoietin-1–Induced Plasticity of Adult Blood Vessels

  2004cited by this paper
• Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis.

  2004cited by this paper
• Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.

  2004influential reference
• Cancer: Out of air is not out of action

  2003cited by this paper
• A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

  2003cited by this paper
• Met, metastasis, motility and more

  2003cited by this paper
• Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.

  2003cited by this paper
• HGF/NK4,a Four-Kringle Antagonist of Hepatocyte Growth Factor,Is an Angiogenesis Inhibitor that Suppresses Tumor Growth and Metastasis in Mice

  2001cited by this paper
• Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

  2001cited by this paper
• Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.

  2000cited by this paper
• HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.

  2000cited by this paper
• Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

  2000cited by this paper
• The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review).

  1998cited by this paper
• Vascular endothelial growth factor is essential for corpus luteum angiogenesis

  1998cited by this paper
• Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth

  1992cited by this paper
• Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes.

  1985cited by this paper

• Cost-effectiveness of cabozantinib versus placebo for advanced neuroendocrine tumors from crossover-adjusted analysis in the United States and China.

  2026cites this paper
• Curation of the Fasciola hepatica kinome as a resource for drug target discovery

  2026cites this paper
• Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy.

  2025cites this paper
• Type XII RTKs: TIE family of angiopoietin receptors in GtoPdb v.2025.3

  2025cites this paper
• Scaffold-hopping strategy for pyrazolo[3,4-d]pyrimidines: In vitro and in silico studies of dual c-Met/STAT3 inhibition for enhanced antitumor activity.

  2025cites this paper
• Type X RTKs: HGF (hepatocyte growth factor) receptor family in GtoPdb v.2025.3

  2025cites this paper
• Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family in GtoPdb v.2025.3

  2025cites this paper
• Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family in GtoPdb v.2025.3

  2025cites this paper
• Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation

  2025cites this paper
• Discovery of KIN-8741, a Highly Selective Type IIb c-Met Kinase Inhibitor with Broad Mutation Coverage and Quality Drug-Like Properties for the Treatment of Cancer.

  2025cites this paper
• Synthesis, Docking, and Machine Learning Studies of Some Novel Quinolinesulfonamides–Triazole Hybrids with Anticancer Activity

  2024cites this paper
• Deciphering tertiary lymphoid structure heterogeneity reveals prognostic signature and therapeutic potentials for colorectal cancer: a multicenter retrospective cohort study

  2024cites this paper
• Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy

  2024cites this paper
• Small molecule-based targeted therapy in liver cancer.

  2024cites this paper
• Discovery of new 1,3-diphenylurea appended aryl pyridine derivatives as apoptosis inducers through c-MET and VEGFR-2 inhibition: design, synthesis, in vivo and in silico studies.

  2024cites this paper
• Case report: A case of Savolitinib in the treatment of MET amplification mutation advanced lung adenocarcinoma with rare bilateral breast metastasis

  2024cites this paper
• Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.

  2024cites this paper
• Angiogenic signaling pathways and anti-angiogenic therapy for cancer

  2023cites this paper
• Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies.

  2023cites this paper
• Design, Synthesis and Biological Evaluation of Quinoline-8-Sulfonamides as Inhibitors of the Tumor Cell-Specific M2 Isoform of Pyruvate Kinase: Preliminary Study

  2023cites this paper
• Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs

  2023cites this paper
• Nanoparticles targeting Sialyl-Tn for efficient tyrosine kinase inhibitor delivery in gastric cancer.

  2023cites this paper
• To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors.

  2023cites this paper
• Discovery of Novel, Thienopyridine-Based Tyrosine Kinase Inhibitors Targeting Tumorigenic RON Splice Variants.

  2023cites this paper
• AXL kinase inhibitors- A prospective model for medicinal chemistry strategies in anticancer drug discovery.

  2022cites this paper
• Predicting circRNA-drug sensitivity associations via graph attention auto-encoder

  2022cites this paper
• Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions.

  2022cites this paper
• The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences.

  2022cites this paper
• Thematic Issue: "Therapy-induced remodeling of Tumor Microenvironment".

  2022cites this paper
• Sprouting Angiogenesis in Human Pituitary Adenomas

  2022cites this paper
• Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications

  2022cites this paper
• Structure-based discovery of receptor tyrosine kinase AXL degraders with excellent anti-tumor activity by selectively degrading AXL and inducing methuosis.

  2022cites this paper
• Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts

  2022cites this paper
• Breaking the Crosstalk of the Cellular Tumorigenic Network in NSCLC by a Highly Effective Drug Combination

  2021cites this paper
• OTT_A_291801 3037..3049

  2021cites this paper
• A Simple Reversed Phase High Performance Liquid Chromatography Method for the Estimation of Related Substances, Assay of Cabozantinib and Nivolumab and its Application to Dissolution Studies

  2021cites this paper
• Identification of an AXL kinase inhibitor in triple‐negative breast cancer by structure‐based virtual screening and bioactivity test

  2021cites this paper
• Low-flow intussusception and metastable VEGFR2 signaling launch angiogenesis in ischemic muscle

  2021cites this paper
• Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models

  2021cites this paper
• OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer

  2021cites this paper
• Synthesis of 4-methyl-2-phenyl-N-(pyridin-2-yl) thiazole-5-carboxamide

  2021cites this paper
• Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor.

  2021cites this paper
• A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

  2021cites this paper
• A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons

  2021cites this paper
• Synthesis of N-(4-fluorophenyl)-1-(pyrrolidine-1-carbonyl) cyclopropane-1-carboxamide

  2021cites this paper
• Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature

  2021cites this paper
• Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors

  2021cites this paper
• Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma

  2021cites this paper
• Concurrent detection of cabozantinib as an anticancer agent and its major metabolites in human serum using fluorescence-coupled micellar liquid chromatography

  2021cites this paper
• Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors

  2021cites this paper
• Prospects for Manipulation of Mesenchymal Stem Cells in Tumor Therapy: Anti-Angiogenesis Property on the Spotlight

  2021cites this paper
• WaterSwap Analysis, a Computation-based Method for the Discovery of Effective and Stable Binding Compounds for Mutant EGFR Inhibition

  2021cites this paper
• Targeting HGF/c-MET Axis in Pancreatic Cancer

  2020cites this paper
• Role of Vitamin K-Dependent Factors Protein S and GAS6 and TAM Receptors in SARS-CoV-2 Infection and COVID-19-Associated Immunothrombosis

  2020cites this paper
• Tyrosine Kinase Receptors in Oncology

  2020cites this paper
• ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models

  2020cites this paper
• YAP Orchestrates Heterotypic Endothelial Cell Communication via HGF/c-MET Signaling in Liver Tumorigenesis

  2020cites this paper
• Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer.

  2020cites this paper
• UPLC–MS/MS assay for quantification of an inhibitor of kinases (Foretinib) in plasma: Application to a pharmacokinetic study in rats

  2020cites this paper
• Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

  2020cites this paper
• Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.

  2020cites this paper
• Response to cabozantinib in renal cell carcinoma with cardiac metastases.

  2020cites this paper
• Cabozantinib as an emerging treatment for sarcoma.

  2020cites this paper
• Discovery of [1,2,4]triazolo[4,3-a]pyrazine derivatives bearing a 4-oxo-pyridazinone moiety as potential c-Met kinase inhibitors

  2020cites this paper
• New Insights Into Implementation of Mesenchymal Stem Cells in Cancer Therapy: Prospects for Anti-angiogenesis Treatment

  2019cites this paper
• Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.

  2019cites this paper
• Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets.

  2019influential citation
• High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer

  2019cites this paper
• Recent Progress in the Development of Small Molecule c-Met Inhibitors.

  2019cites this paper
• A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors

  2019cites this paper
• Anti-tumor effects of anti-Semaphorin 4D antibody unravel a novel pro-invasive mechanism of vascular targeting agents.

  2019cites this paper
• Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer

  2019cites this paper
• Anti-tumor effects of anti-Semaphorin 4D antibody unravel a novel pro- 1 invasive mechanism of vascular targeting agents 2

  2019cites this paper
• OTT_A_211535 7215..7226

  2019cites this paper
• Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer

  2019cites this paper
• (±)-trans-Dihydronarciclasine and (±)-trans-dihydrolycoricidine analogues modified in their ring A: Evaluation of their anticancer activity and a SAR study.

  2019cites this paper
• Angiogenesis and Metastasis with a Therapeutic Approach: A Review

  2019cites this paper
• EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling.

  2019cites this paper
• CMAR_A_215533 7787..7803

  2019cites this paper
• AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

  2019cites this paper
• Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms

  2019cites this paper
• Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles.

  2019cites this paper
• Downregulation of miR-21 inhibits the malignant phenotype of pancreatic cancer cells by targeting VHL

  2019cites this paper
• Targeted drug combination therapy design based on driver genes

  2019cites this paper
• Investigational MET inhibitors to treat Renal cell carcinoma

  2019cites this paper
• MALAT1 regulates miR-34a expression in melanoma cells

  2019cites this paper
• Design, Synthesis and Biological Evaluation of 6,7-Disubstituted-4-phenoxyquinoline Derivatives Bearing Pyridazinone Moiety as c-Met Inhibitors

  2018cites this paper
• Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma

  2018cites this paper
• Discovery of thinopyrimidine-triazole conjugates as c-Met targeting and apoptosis inducing agents.

  2018cites this paper
• A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer

  2018cites this paper
• Survivin is critically involved in VEGFR2 signaling-mediated esophageal cancer cell survival.

  2018cites this paper
• Design, synthesis and molecular modeling study for some new 2-substituted benzimidazoles as dual inhibitors for VEGFR-2 and c-Met.

  2018cites this paper
• Axl inhibitors as novel cancer therapeutic agents.

  2018cites this paper
• Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.

  2018cites this paper
• A Systems Chemical Biology Approach for Dissecting Differential Molecular Mechanisms of Action of Clinical Kinase Inhibitors in Lung Cancer

  2018cites this paper
• Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).

  2018cites this paper
• Synthesis and antiproliferative activity of pyrrolo[2,3-b]pyridine derivatives bearing the 1,8-naphthyridin-2-one moiety.

  2018cites this paper
• Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.

  2017cites this paper
• Discovery of novel 2-substituted-4-phenoxypyridine derivatives as potential antitumor agents.

  2017cites this paper
• Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy

  2017cites this paper